Stereotactic body radiation therapy in patients with oligometastatic disease: Clinical state of the art and perspectives
R Kinj, E Muggeo, L Schiappacasse, J Bourhis… - Cancers, 2022 - mdpi.com
Simple Summary Stereotactic radiation therapy (SBRT) is a type of radiation therapy in
which a small number of high doses of radiation are delivered to a target volume using …
which a small number of high doses of radiation are delivered to a target volume using …
Impact of high dose radiotherapy for breast tumor in locoregionally uncontrolled stage IV breast cancer: a need for a risk-stratified approach
Aim Patients with locoregionally uncontrolled breast tumors are frequently referred for breast
palliative radiotherapy (PRT) to mitigate symptoms. We analyzed the outcomes following …
palliative radiotherapy (PRT) to mitigate symptoms. We analyzed the outcomes following …
Combination of olaparib with radiotherapy for triple‐negative breast cancers: one‐year toxicity report of the RADIOPARP phase I trial
P Loap, D Loirat, F Berger, K Cao… - … journal of cancer, 2021 - Wiley Online Library
Triple‐negative breast cancer (TNBC) cells are sensitive to PARP1 inhibitors in vitro. The
combination of Olaparib and radiotherapy for TNBC is currently evaluated in the Phase I …
combination of Olaparib and radiotherapy for TNBC is currently evaluated in the Phase I …
Radiotherapy of the primary disease for synchronous metastatic cancer: a systematic review
Simple Summary Local radiation treatment of the main tumors in patients with synchronous
metastatic illness has traditionally only been used for palliative purposes. The management …
metastatic illness has traditionally only been used for palliative purposes. The management …
Outcomes and toxicity of concurrent CDK4/6 inhibitor and locoregional radiotherapy for patients with de novo metastatic breast cancer
The objective of the present study was to assess the outcomes and toxicity of patients
treated with concurrent administration of CDK4/6 inhibitors (CDK4/6i) and locoregional …
treated with concurrent administration of CDK4/6 inhibitors (CDK4/6i) and locoregional …
Pertuzumab and trastuzumab combination with concomitant locoregional radiotherapy for the treatment of breast cancers with HER2 receptor overexpression
A Aboudaram, P Loap, D Loirat, SB Dhia, K Cao… - Cancers, 2021 - mdpi.com
Simple Summary This retrospective study demonstrates that the combination of locoregional
breast RT with dual HER2 blockade by pertuzumab/trastuzumab was very well tolerated …
breast RT with dual HER2 blockade by pertuzumab/trastuzumab was very well tolerated …
Aggressive local therapy for de novo metastatic breast cancer: Challenges and updates
B Liu, H Liu, M Liu - Oncology Reports, 2023 - spandidos-publications.com
Systemic therapy has been viewed as the mainstay for de novo metastatic breast cancer
(dnMBC). However, as dnMBC is highly heterogeneous both biologically and clinically, and …
(dnMBC). However, as dnMBC is highly heterogeneous both biologically and clinically, and …
Radiotherapy to the primary tumor: the first step of a tailored therapy in metastatic prostate cancer
M Ferro, F Crocetto, G Lucarelli, E Lievore, B Barone - Diagnostics, 2022 - mdpi.com
Prostate cancer is the first most frequent cancer in men worldwide, with over 250,000
estimated new cases diagnosed in 2021 [1]. Primary treatment modalities mostly include …
estimated new cases diagnosed in 2021 [1]. Primary treatment modalities mostly include …
Is there a role for locoregional treatment of the primary tumor in de novo metastatic breast cancer in the era of tailored therapies?: Evidences, unresolved questions …
E Pons-Tostivint, E Alouani, Y Kirova, F Dalenc… - Critical reviews in …, 2021 - Elsevier
Improvements in systemic therapies have changed the face of de novo metastatic breast
cancer (dnMBC), with a 5-year survival rate exceeding 25%. Increasing evidence suggests …
cancer (dnMBC), with a 5-year survival rate exceeding 25%. Increasing evidence suggests …
Radiation therapy of the primary tumour and oligometastatic sites in patients with breast cancer with synchronous metastases: a literature review
R Le Scodan, Y Ghannam, Y Kirova, C Bourgier… - Cancer …, 2024 - Elsevier
De novo metastatic breast cancer represents 5 to 8% of all breast cancers (2500 new cases
per year in France). Systemic treatment is the cornerstone of treatment, whereas radiation …
per year in France). Systemic treatment is the cornerstone of treatment, whereas radiation …